GLP-1 Prior Authorization Denials Highlight Barriers to Obesity Treatment
Key Takeaways:
- Among 225 000 commercially insured adults with obesity, coverage without prior authorization (PA) was rare, with most cases involving some kind of PA requirement.
- Over one-third of patients with initial PA submissions were denied coverage, illustrating how PA policies can limit drug access.
- Coverage limitations and clinical ineligibility were cited as primary reasons for PA denial, highlighting the need for benefit redesign and policy reform.
An abstract presented at ObesityWeek 2026 examined coverage and PA patterns for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among commercially insured adults with obesity.
GLP-1 RAs are effective weight-management medications that are often prescribed as first-line therapies for patients with obesity or overweight. However, high drug costs and limited insurance coverage pose significant access barriers.
Study Methods and Outcomes
Using clinical and insurance data from a telehealth platform, researchers conducted a retrospective observational study to assess coverage patterns and PA outcomes.
Eligible patients had either a body mass index (BMI) between 27.0 and 30.0 kg/m² with at least 1 obesity-related complication or a BMI greater than 30.0 kg/m².
All participants had completed medication-specific verification of benefits (VOB) for GLP-1 RAs between January and September 2025. Benefits were categorized as coverage without PA, coverage with PA, plan exclusion, or indeterminate.
Study results were assessed across the following domains: medication, payer/pharmacy benefit manager (PBM), geographical region, patient demographics, and clinical characteristics.
Drug Access Restricted by PA Policies
The study included 225 000 patients with obesity, with most receiving coverage with PA. Among those who had coverage with PA, 35.7% were for semaglutide and 31.1% were for tirzepatide.
Few patients received coverage without PA (3.7% for semaglutide and 2.8% for tirzepatide). Approximately 27.0% of VOBs for each therapy were indeterminate.
Among the 69 462 patients with initial PA requests, 53.2% were approved, 35.7% were denied, and 11.2% were unknown. Denials were primarily due to plan exclusions or coverage limitations, clinical ineligibility, and unmet treatment requirements.
PA denials were more common among patients with a BMI between 27.0 and 29.9 kg/m² and at least 1 obesity-related complication, with clinical ineligibility being the most common reason for denial.
Patients with a BMI of 40.0 kg/m² or greater had higher rates of plan exclusions or coverage limitations compared to other BMI groups.
Researchers observed greater variation of VOB and PA patterns across payer/PMB and geographical regions compared to patient demographics or clinical characteristics.
Implications for Managed Care
These findings reflect GLP-1 RA access barriers relating to restrictive coverage policies and PA requirements.
Among adults with obesity, coverage without PA was uncommon, and over one-third of initial PA submissions were denied, highlighting the need for policy reform aimed at improving access.
According to the authors, “This highlights a gap in understanding coverage and authorization processes when supporting clinically eligible patients seeking standard-of-care obesity treatment.”
Reference
Broffman L, Smith B, Manalac R, et al. Clinical eligibility and coverage gaps for GLP-1–based receptor agonists in patients with obesity. Poster 531. Abstract presented at: ObesityWeek 2026; November 14-17, 2026; Washington, DC.


